Dasatinib is unique in its ability to induce expansion of large granular lymphocytes (LGLs), consisting of mono- or oligo-clonal CD8+ T cells and NK cells, shown to correlate with better prognosis and consequently more favorable response in patients with CML (109–112). The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.